China

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2

Lead Product(s): PiCoVacc

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Study will evaluate the safety, tolerance, and preliminary immunogenicity of the Sinovac's SARS-CoV-2 vaccine by vaccinating 144 healthy adults, with two different dosages of the vaccine candidate.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19

Lead Product(s): Inactivated SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2020

Details:

This study is to evaluate the safety, tolerance, and preliminary immunogenicity of the Company’s SARS-CoV-2 vaccine by vaccinating healthy adults, with two different dosages of the vaccine candidate.

I-Mab Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Three Research Sites to Lead Clinical Trial of I-Mab’s of TJM2 to Counter COVID-19’s Deadly Cytokine Storm

Lead Product(s): TJM2

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 12, 2020

Details:

I-Mab got by the U.S.FDA to conduct a Phase I clinical trial to assess its investigational product TJM2 to treat cytokine release syndrome associated with severe illness caused by COVID-19.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Sinovac Biotech

Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2

Sinovac Biotech

Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19

I-Mab Biopharma

Three Research Sites to Lead Clinical Trial of I-Mab’s of TJM2 to Counter COVID-19’s Deadly Cytokine Storm